invasive aspergillosis – Page 3

Appearance of Environment-Linked Azole Resistance in the Aspergillus fumigatus Complex in New Zealand

mycolabadmin

Researchers in New Zealand have discovered that a dangerous fungus called Aspergillus fumigatus is developing resistance to commonly used antifungal medications. Unlike previous cases where the resistance came from medical treatment, this new resistance appears to come from environmental exposure, possibly through garden fungicides that people can buy at garden centers. The study found that people, especially lung transplant patients, may be acquiring these resistant fungal strains from their surroundings rather than from hospitals, highlighting the need for better monitoring of agricultural fungicide use.

Evaluating the Potential of Galactosaminogalactan as a Diagnostic Target for Invasive Aspergillosis

mycolabadmin

Researchers developed a new test to detect Aspergillus fungal infections using an antibody that recognizes a fungal component called GAG. The test worked very well in mouse studies, reliably detecting the fungus in blood and other body fluids. However, when tested with samples from infected patients, the test could not find GAG in the blood or other fluids, though it could see the fungus in lung tissue. This suggests either patients don’t produce enough GAG in their bloodstream, or something in human biology interferes with detection.

Roles of the Sec2p Gene in the Growth and Pathogenicity Regulation of Aspergillus fumigatus

mycolabadmin

Researchers studied a gene called Sec2p in a dangerous fungus that causes serious lung infections in people with weak immune systems. By removing this gene, they found the fungus grew slower, caused less damage, and fewer infected mice died. This discovery suggests that blocking Sec2p could be a new way to treat these fungal infections.

Acute Respiratory Distress Syndrome Due to COVID-19-Associated Pulmonary Aspergillosis with Rare Extensive Tracheobronchial Pseudomembranous Involvement: A Case Report

mycolabadmin

An 87-year-old man with COVID-19 developed a rare and severe fungal infection in his airways caused by Aspergillus fumigatus. Doctors used a camera tube (bronchoscope) to see thick, yellowish-white membrane-like material coating his entire windpipe and airways, which is an extremely rare complication. Despite starting antifungal medications, his condition rapidly worsened leading to organ failure and death. This case highlights how COVID-19 can leave patients vulnerable to serious secondary fungal infections that require immediate recognition and treatment.

Phospholipase PlcH is involved in the secretion of cell wall glycoproteins and contributes to the host immune response of Aspergillus fumigatus

mycolabadmin

Researchers discovered that an enzyme called PlcH helps a dangerous mold called Aspergillus fumigatus release protective proteins into its cell wall. These proteins help the fungus survive and evade the immune system. When scientists removed the gene for PlcH, the fungus became weaker and more vulnerable to both antifungal drugs and immune cells, suggesting PlcH could be a target for new antifungal treatments.

The cyclase-associated protein contributes to antifungal susceptibility and virulence in Aspergillus fumigatus

mycolabadmin

Researchers found that removing a specific protein called CAP from a dangerous mold called Aspergillus fumigatus makes it much weaker and easier to kill with antifungal drugs. This mold normally causes serious lung infections in people with weak immune systems. The study showed that CAP helps the mold grow and resist medicines, and blocking it could be a new way to treat these dangerous infections.

The frequency distribution of Aspergillus section Nigri from clinical and environmental samples in Iran

mycolabadmin

Researchers studied black mold species (Aspergillus section Nigri) found in hospitals and the environment across Iran. They identified eight different species and found that certain types like A. welwitschiae were more common in ear infections while A. tubingensis was more prevalent in soil and air. These findings are important because some of these molds cause serious infections in humans and understanding where they live helps doctors predict and treat infections.

Identification of Non-fumigatus Aspergillus Species in Clinical Samples from Southern California

mycolabadmin

Researchers studied fungal infections caused by Aspergillus in Southern California from 2012 to 2023, examining over 10,000 patients. They found that species other than the commonly known A. fumigatus were actually more prevalent in clinical samples, particularly A. niger from skin and nail infections. Importantly, these non-fumigatus species showed seasonal patterns and some carry resistance to standard antifungal medications, suggesting doctors may need to adjust their treatment approaches for fungal infections.

BTK drives neutrophil activation for sterilizing antifungal immunity

mycolabadmin

BTK is a protein that helps neutrophils (immune cells) fight fungal infections, particularly Aspergillus fumigatus. A cancer drug called ibrutinib blocks BTK, which weakens neutrophil antifungal responses and increases the risk of serious fungal infections. The study found that GM-CSF may help restore some immune function in patients taking BTK-blocking drugs, offering a potential strategy to prevent these dangerous infections.

Genome sequences of Aspergillus fumigatus strains isolated from wildfowl in Southern Ontario, Canada

mycolabadmin

Researchers sequenced the genomes of four Aspergillus fumigatus fungi isolated from infected birds (an osprey, peregrine falcon, and two hawks) brought to wildlife rehabilitation centers in Ontario. This fungus causes a serious infection called aspergillosis that damages the lungs and air sacs of birds. The genetic information from these four strains is now publicly available for scientists studying how this fungus infects birds and how it resists antifungal treatments.

Research Keyword: invasive aspergillosis